VSTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Verastem, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.62−0.03 (-0.35%)
Close on Oct 19, 2026
- Market cap
- $863.00M
- P/E (TTM)
- –
- Dividend yield
- –
Verastem, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $30.91M | – | – | – | – | $15.23M | $12.34M | $1.72M | 100.0% | – |
| License and collaboration revenue | – | – | – | – | – | $2.91M | $5.12M | $25.00M | – | – |
| Sale of COPIKTRA license and related assets | – | $10.00M | – | $2.60M | $1.45M | $70.00M | – | – | – | – |
| Transition Services Revenue | – | – | – | – | $606.00K | $372.00K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Verastem's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.